by Francisca Peixoto | Mar 23, 2023 | Uncategorized
Our portfolio company Macomics announces that it has entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical (a leader in immuno-oncology) to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in...
by Francisca Peixoto | Jan 17, 2023 | Uncategorized
Our portfolio company Spiral Therapeutics announces the completion of $8.25M in new financing, with proceeds that will fund the continuing development of their lead candidate, SPT-2101, for the treatment of inner ear inflammation. SPT-2101 is a sustained-release...
by Francisca Peixoto | Jan 5, 2023 | Uncategorized
As we start the new year, LifeLink Ventures releases its 2022 Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
by Francisca Peixoto | Nov 15, 2022 | Uncategorized
The BioTech Breakthrough Awards recognizes “the world’s best life sciences and biotech companies, their products and their services” and, in the 2nd annual BioTech Breakthrough Awards, our portfolio company Chameleon Biosciences has been named Immunomodulatory...
by Francisca Peixoto | Oct 28, 2022 | Uncategorized
Ochre Bio has announced their Scientific Strategy Board. This group of brilliant minds recently spent a day together in New York, to talk through Ochre’s scientific approach and future planning. Sangeeta Bhatia – Wilson Professor of Engineering, MIT...
